Chronic Pancreatitis as an Inductor of Pancreatic Cancer — Correlations With Inflammatory Pathways by Dima, Simona Olimpia et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 11
Chronic Pancreatitis as an Inductor
of Pancreatic Cancer — Correlations
With Inflammatory Pathways
Simona Olimpia Dima, Dana Cucu,
Nicolae  Bacalbasa and Irinel Popescu
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/59714
1. Introduction
The immune system and inflammation are processes with dual roles in cancer development.
Firstly, immunity responds to the presence of a tumour by producing anti-inflammatory
agents with the role of restoring the homeostasis and improving adverse health effects. On the
other hand, immune cells create a tumoural microenvironment which supports angiogenesis,
cell proliferation and migration, being thus correlated with cancer initiation and progression.
In the same vein, recent studies show correlations between pancreatic inflammation and
pancreatic cancer (reviewed in [1]). The most common causative agents of both conditions are
generally considered alcoholism, smoking, toxic-metabolic and genetic factors. Because
chronic pancreatitis is taken into account as an etiological issue of pancreatic cancer progress,
this review aims to explain the molecular pathways from inflammation to pancreatic carcino‐
genesis, in support of the prevention, diagnosis and therapies of this dreadful disease.
Moreover, inflammatory mediators are connected to pain and cachexia, the associated
conditions that dramatically affect quality of life in pancreatic cancer. In this context, it is clear
that the evaluation of the cellular pathways from inflammation to cancer is an important step
in revealing the mechanisms underlying cancer development and opening new avenues for
possible therapies. In this chapter, the common features of chronic pancreatitis and pancreatic
cancer linked by the inflammatory process will be presented along with some of the anti-
inflammatory therapies proposed so far.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
2. Incidence of chronic pancreatitis and pancreatic cancer
Over the last years, many studies have reported an increased burden of pancreatic disorders
that is expected to amplify even more over time. Acute, chronic pancreatitis and pancreatic
cancer are the major disorders described which affect the exocrine pancreas. Acute pancreatitis
is the condition with the higher incidence, between five and 80/ 100,000 people annually being
reported worldwide [2], and it is considered as one of the most frequent gastrointestinal
diseases for admission in hospitals in the US [3]. The annual incidence of chronic pancreatic
(CP) is much lower. In Europe and other regions six to seven/ 100,000 persons are affected [4]
with a slight increase in China and India [5]. Despite its lower incidence as compared to acute
pancreatitis and because of disease exacerbation and secondary endocrine deficiencies, it
dramatically impacts quality of life [6]. Although in industrialized countries, CP cases are
associated with long alcohol consumption, about 10-30% of them were attributed to unknown
causes. In these instances, the term idiopathic CP is used. An important change in the under‐
standing of the disease comes from genetic studies which show that idiopathic CP mainly has
a genetic background [7].
3. The role of inflammatory modulators in chronic pancreatitis and the
development of pancreatic cancer
Pancreatic cancer is a cancer with a lower incidence, but with one of the worst prognoses. From
among the many types of pancreatic tumours, 75% of pancreatic cancers refer to pancreatic
ductal adenocarcinoma (PDA). In an attempt to describe and cure these pancreatic diseases
(CP and PDA) the insightful question raised is whether there is a continuum of events among
them or whether each should be considered as an independent condition. The hypothesis of
CP-PDA interplay is based on the connection between chronic inflammation and the increased
risk of cancer of the organ affected [8].
Moreover, in the last years, it has become clear that inflammation may be, at least in part,
responsible for fibrosis of the pancreatic tissue. Chronic pancreatitis is characterized by
progressive, recurrent pancreatic injury leading to fibrosis, ductal and exocrine atrophy and
inflammatory response. In the last years, pancreatic stellate cells (PaSCs) have caught the
attention of the scientific community, being described as a principal source of fibrosis [9].
During the course of chronic pancreatitis, the fibrotic response depends on the activation of
PaSCs, which produce the extracellular matrix (ECM) proteins from the pancreatic tumour
stroma [10]. PDA is also characterized by a strong desmoplastic reaction, such that ~90% of
the tumour volume is represented by stromal content, a feature specific to PDA. Activated
PaSCs were also observed in the vicinity of pancreatic epithelial lesions [11]. Therefore, over
the last years many studies have concentrated on the signalling pathways and bidirectional
influence between PaSCs, PDA and chronic pancreatitis. Molecular studies showed that ECM
synthesis is mediated by the transforming growth factor β1 (TGF-β1) and the fibroblast growth
factor (FGF), whereas PaSCs proliferation is supported by ciclooxygenase-2 [11]. In addition
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to fibrosis, PaSCs may mediate PDA-associated inflammation via intricate paracrine interac‐
tions with inflammatory cells, acinar cells and PDA cells. During the development of chronic
pancreatitis or PDA acinar pancreatic cells, immune cells and endothelial cells produce
cytokines and growth factors which have the ability to activate PaSCs. Stellate cells also may
secrete cytokines and growth factors.
Despite these recent data, the exact link between the long-standing process of CP and pancre‐
atic carcinogenesis remains an open question.
As mentioned above, many inflammatory mediators that exist in CP have also been linked to
PDA [12]. Inflammatory processes consecutive to ductal or acinary injury represent the
activation of the immune system that releases pro-inflammatory factors in order to prevent
the harmful effect. These factors include cytokines (tumour necrosis factor (TNF-α), trans‐
forming growth factor (TGF) β interleukins (IL-1, IL-6, and IL-8), chemokines (e.g., monocyte
chemoattractant protein-1, macrophage inflammatory protein-1, monocyte chemoattractant
protein-1, and growth-related oncogenes), adhesion molecules, reactive-oxygen and reactive-
nitrogen species. Many of these inflammatory products could also be involved in tumouri‐
genesis. In the digestive system, inflammation has been described in gastric carcinoma
subsequent to persistent Helicobacter pylori [13], colorectal cancer associated with inflamma‐
tory bowel disease [14, 15] and oesophageal adenocarcinoma following reflux esophagitis [16].
When treated inadequately, chronic inflammation may increase the risk of cancer, both
processes sharing the same signalling pathways in increased proliferation rate, apoptosis,
angiogenesis.
One mechanism that enhances the risk of cancer and strongly relates to the inflammatory
process is the infiltration of immune products into the tumour microenvironment. There is
also abundant evidence that pro-inflammatory cytokines and their receptors are expressed in
pancreatic cells and infiltrating immune cells within inflamed pancreatic tissues [17, 18]. We
review in the next paragraphs the best described pro-inflammatory mediators and their
participation in chronic pancreatitis and PDA.
3.1. Tumour Necrosis Factor (TNF-α)
Tumour necrosis factor (TNF-α) is a cytokine produced especially by activated macrophages
but also by other cells (e.g., fibroblasts, keratinocytes) as a pro-inflammatory cytokine. and in
concequence participates in regulating the cellular homeostasis and the defence of the harmed
organisms. In the immune systems, TNF-α contributes to the correct functioning of NK cells,
B cells and T cells. Other results suggest that besides these important roles, TNF-α is associated
with chronic inflammatory diseases and ultimate tumourigenesis. [19].
TNF-α was first describe by Carswell et al. [20] and many following studies have shown
that  immune  cells  produce  two  types  of  tumour  necrosis  factors:  TNF-α  produced  by
activated macrophages and TNF-β produced by mitogen stimulated lymphocytes. Pioneer‐
ing studies by Balkin et al. [21] showed that TNF-α is a tumour promoter of skin cancer.
An anti-tumour necrosis  factor-alpha antibody inhibits  the development of  experimental
skin tumours [22]. Thereafter, many studies have pointed out that this cytokine has a role
Chronic Pancreatitis as an Inductor of Pancreatic Cancer — Correlations With Inflammatory Pathways
http://dx.doi.org/10.5772/59714
209
in autoimmune diseases, chronic inflammatory processes and, despite its name, in malignan‐
cy. Systemic levels of TNF-α together with various cytokines such as IL-6, Il-8, IL-10 were
found to be significantly higher in patients with PDA compared to healthy subjects [23, 24].
PDA cells are exposed to TNF-α secreted by the infiltrated macrophages but also to their
own endogenous TNF-α.
The  major  role  of  this  cytokine  is  to  switch  between  inflammatory  and  tumourigenic
processes thus stimulating the ability of cancer cells to undergo migration and invasion.
The  detailed  signalling  pathways  through  which  TNF-α  exerts  this  role  are  yet  to  be
revealed. However, the TNF-α receptors are well-described (TNF-R1 and TNF-R2). While
TNF-R2 is expressed only in endothelial and immune cells, TNF-R1 was described in many
tumoural  tissues  including  PDA.  After  binding  to  its  ligands,  TNF-α receptors  suffer  a
conformational  change  leading  to  a  stable  trimeric  form  and  subsequent  activation  of
various signalling pathways. On the one hand, the NF-κb pathway may be activated and
this will trigger the inflammatory response, anti-apoptotic processes and cell survival. On
the other hand, TNF-α may induce the activation of the mitogen- activated protein kinase
(MAPK) signalling pathway with subsequent effects on proliferation, differentiation, and
apoptosis of cells. These rather conflicting signals raised even more questions whether TNF-
α  may  be  used  as  a  PDA  therapeutic  target.  Following  the  anti-apoptotic  signalling
inhibitors of TNF-α infliximab and etanercept were proposed as possible therapeutic agents
in  PDA,  especially  after  pancreaticoduodenectomy  [25].  Interestingly,  both  anti-TNF
compounds are currently used for the treatment of chronic inflammation. However,  this
study and others were not able to prove that TNF-α is the missing link between chronic
pancreatitis  and  PDA,  but  the  results  obtained  so  far  using  inhibitors  of  this  cytokine
support this assumption.
3.2. Interleukine-6 (IL-6)
Many other interleukins have increased levels in PDA as well as in CP. Among them, Inter‐
leukine-6 was systematically described in many studies as a pro-inflammatory cytokine
overexpressed in PDA tumours and in the systemic circulation of patients. Moreover, high
levels of IL-6 in the serum of diseased persons directly correlate with increased mortality [26,
27]. IL-6 binds to its specific receptor formed by two subunits; one ligand-specific IL-6Rα and
one signal transducer gp130. The intracellular domain of gp130 activates the Junus Kinase
(JAK) and MAPK pathways. JAK activates the transcription factor STAT3 involved in invasion
and metastasis, and identified in many tumours including PDA [28]. The inhibition of the
STAT3 phosphorylation pathway was considered a good therapeutic approach in previous
studies [29]. Although IL-6 has shown high levels in chronic pancreatitis, a genetic analysis
failed to prove a correlation with the prognosis for this condition [30].
The role of IL-6 and the signalling pathway has yet to be investigated because it is clear that
CP is a factor in the development of PDA.
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3.3. Cyclooxygenases
Cyclooxygenases (COX-1 and COX-2), also known as prostaglandin (PG) endoperoxide
synthases, are isoenzymes required for in the conversion of arachidonic acid to prostaglandins.
COX-1 and-2 share ~65 structural similarities and have almost identical catalytic domains.
COX-1 is a constitutive enzyme and is produced by almost all cells in normal physiological
processes, whereas COX-2 is an inducible enzyme with almost undetectable levels in normal
cells and with a high expression in many cancer types including PDA [31]. Importantly, COX-2
is induced by inflammatory factors, therefore, it may be one of the mediators between chronic
pancreatitis and PDA. The strongest evidence that favours this link comes from a mouse model
(BK5.COX-2) in which the over-expression of COX-2 induces pancreatic acinar to ductal
metaplasia progression to severe dysplasia [32]. In this model the authors have shown that all
transgenic mice develop pancreatic inflammation and metaplasia specific to human CP.
Afterward, the initiation of dysplastic lesions featuring PDA was observed. This is one of the
most convincing models that favour COX-2 as a key modulator of a tumour microenvironment
in response to inflammatory stimuli.
3.4. Transforming Growth Factor (TGF)-β
Transforming growth factor (TGF)-β is a cytokine which inhibits cell proliferation and
modulates the immune response. In normal pancreas it blocks the G1/S phase cell cycle
progression, whereas in pancreatic cancer it decreases suppressive activity through an
impairment of the signalling pathway [33]. It was shown that (TGF)-β is involved in pancreatic
fibrosis, because collagen synthesis was augmented secondary to exogenous cytokine treat‐
ment. Moreover, in a rat model of caerulein-induced pancreatitis the levels of (TGF)-β were
upregulated [34].
The above presented results match the hypothesis that inflammatory products are the
hallmarks of pancreatic cancer and that they can bridge the conceptual gap between idiopathic
CP and PDA. The inflammatory products operate by shifting this pathway into a tumourigenic
one and promote cellular proliferation, invasion and migration. To do so they have to activate
oncogenic networks of transcription factors throughout the regulation of specific genes.
4. Oncogenes and tumour suppressor genes common in chronic pancreatitis
and pancreatic adenocarcinoma
In the last years, many studies have reported the detection of proto-oncogenes and tumour
suppressor gene mutations in the pathogenesis of CP and PDA. Developments in molecular
biology and biotechnologies such as ADN microarrays for genome-wide chromosomal
localization enable the detection of genetic causes in both conditions. Oncogenes are genes that
when mutated have the potential to cause cancer, whereas transcription factors represent a
group of proteins that regulate gene transcription by binding to specific DNA sequences and
modulate mRNA synthesis.
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4.1. K-Ras proto-oncogene
One of the genes involved in CP may be the K-Ras proto-oncogene. The product of K-Ras gene
is a small GTPase protein and a key player in many intracellular signalling processes. As all
GTPase molecules, K-Ras has an enzymatic activity that relies on the conversion of GTP to
GDP, consistent with the active state of the protein. The switch from the active to the inactivate
state is mediated by GTPase-activating proteins (GAP), whereas the activation of K-Ras is
promoted by guanine nucleotide exchange proteins (GEFs). In pancreatic cancer one point
mutation of the encoding K-Ras gene at codon G12 impairs the inactivation of K-Ras, placing
the protein in a permanent active state. All the downstream signalling pathways are subse‐
quently perturbed and thus drive the processes characteristic to cancer [35]. The main process
generated by the K-Ras mutation is the activation of the inflammatory microenvironment and
subsequent fibrosis. Without any doubt, K-Ras mutation is observed in most PDA. However,
a new concept has come out, centred around the mutation level that K-Ras has to reach in order
to initiate PDA. This new idea is based on studies showing that healthy people have high levels
of K-Ras oncogens at rates exceeding cancer patients. In other words, expression of the
oncogenic K-Ras from its endogenous locus is insufficient to activate downstream signaling
pathways, so that a pathological threshold is necessary for K-Ras mutation to be reached in
order to initiate PDA. When non-endogenous levels are reached, CP and not PDA will develop,
at least in one mouse model [36]. These results became extremely important in showing that
K-Ras mutation is not important per se in PDA, but rather the level of the subsequent activated
signalling pathway. This discrete modulation may be the reason why attempts to inhibit this
molecule as a cancer therapy, failed.
Moreover, the same studies suggest the oncogenic K-Ras accelerates tumour development only
in an inflammatory milieu in the sense that inflammatory mediators activate the oncogenic K-
Ras, which in turn stimulates the desmoplastic reaction. These results are consistent with data
obtained from patients showing that 30% of CP persons bear a K-Ras mutation. Therefore, the
idea that the K-Ras mutation is a PDA marker should be reconsidered in the context of the
inflammatory environment.
4.2. Notch
Notch is another well described oncogene in PDA and experimental CP in mice is connected
to the upregulation of Notch and acinar to ductal metaplasia. The Notch gene encodes for
transmembrane proteins that regulate the mechanism of lateral inhibition during embryogen‐
esis. Using mice with induced Notch activity, it was shown that only upon coactivation with
K-Ras, Notch initiates the promotion of pancreatic lesions [37]. Moreover, using cDNA
microarray technology, deregulated Notch pathways were found in CP [38]. This study
showed that Notch receptors, Notch1 and Notch2, as well as Notch targets such as HES-related
repressor protein, were upregulated in CP. Another study showed how crosstalk between
TNF-α and Notch sustains the intrinsic inflammatory profile of pancreatic cancer cells [39].
TNF-α stimulates the transcription factor NF-κB signalling and, together with Notch signals,
induced the optimal expression of Notch targets. The enhancement of these target genes
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suppresses the anti-inflammatory protein expression and creates a feedback loop that keeps
the cells in an inflammatory state.
4.3. Transcription factor Nf-κB
The transcription factor Nf-κB was initially described in activated B lymphocytes and there‐
after characterised in almost every cell. It controls the activity of ~ 150 genes and the biological
answers to various external stimuli. Nf-κB is a heterodimeric protein sequestered in the
cytoplasm by IκB protein. In response to different stimuli (including those of inflammatory
origin), IκB is phosphorylated and then degraded. The IκB proteolysis permits the release of
Nf-κB and translocation to the nucleus where it binds to specific promoter regions and initiates
gene transcription. Several studies indicate that Nf-κB is constitutively expressed in PDA cell
lines, in humans and animal models of pancreatic cancer with functions in proliferation,
resistance to apoptosis and inflammation-induced cancer development [40, 41]. Importantly,
active Nf-κB was determined in experimental models of pancreatitis and was asserted as an
early response to inflammation [42]. Other experiments sustain a model in which Nf-κB
positively links the oncogenic Ras signalling and the inflammatory process [43]. Augmented
values of Nf-κB mRNA favour pro-apoptotic pathways in acinar cells, whereas the islets are
not affected. From these results, the authors concluded that in CP only the endocrine cells may
be subjected to cell reprogramming by evading immune attack, whereas exocrine cells exibit
an altered state resulting from Nf-κB transcriptional activity [44].
In a caerulein-induced pancreatitis mouse model NF-κB activation was described [45]. NF-κB
activation promotes inflammation and the milieu that favours cancer development [46].
Other transcription factors with oncogenic potential activated by inflammation and described
in pancreatic cancer are: i) Nuclear factor of activated T-cells (NFATc1) that belongs to the
same family as NF-κB and regulates genes participating in cell growth and differentiation, and
ii) the GLI1 family important for tumour microenvironment modulation, cell apoptosis,
autophagy and proliferation.
5. Other molecular markers for PDA and/or CP involved in inflammation
5.1. The fibroblast-specific protein 1
A factor that may mediate the cross talk between PDA cells and inflammation is the fibroblast-
specific protein 1 or S100A4. S100A4 is an important player in metastatic dissemination, and
increased expression of the protein has been associated with poor prognosis in various human
cancer types [47]. The metastasis-promoting protein S100A4 belongs to the S100 family of
calcium-binding proteins, but its function has not yet been well described. The protein seems
to exert dual, intracellular and extracellular functions that may contribute to its pro-metastatic
effects [48, 49]. S100A4 is expressed in many cancer cells [50, 51] and in several types of stromal
cells, e.g., fibroblasts, lymphocytes, macrophages [52-54]. Previous studies showed that in PDA
patients, S100A4 together with S100A2 are associated with more aggressive tumours and
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predict worse survival after surgery. These two markers are proposed to stratify resectable
pancreatic cancer into different phenotypes of prognosis and response to therapy. S100A4 is
also secreted by PDA cell lines in vitro [51, 55] and can be detected in the tumour interstitial
fluid [52], suggesting a role for S100A4 in the tumour-stroma interplay.
5.2. Transforming Growth Factor (TGF)-α
Transforming growth factor (TGF)-α is a polypeptide that induces mitogenic and cell differ‐
entiation responses. The specific receptor is the tyrosine kinase EGF receptor (EGFR) common
for (TGF)-α and epidermal growth factor. The overexpression of both TGF-α and EGFR were
upregulated in CP and in pancreatic cancer. Apparently,TGF-α excessively stimulates EGFR
contributing in this way to the pathology of these diseases [56].
6. Prophylactic and therapeutic use of the anti-inflammatory agents in CP
and PC
Chronic inflammation connected to CP triggers the progression to cancer through the occur‐
rence of the following precancerous lesions: pancreatic intraepithelial neoplasia (PanINs),
intraductal papillary mucinous neoplasms (IPMN), and mucinous cystic neoplasms (MCN).
The progression of these lesions into pancreatic ductal adenocarcinoma (PDA) involves many
diverse molecular pathways.
Many studies published so far have shown increased incidence of pancreatic cancer in CP
patients [57]. The cumulative risk of PC in subjects with CP is 1.8% after 10 years and 4% after
20 years, with an incidence ratio of 1.8% [58]. Over the last few years a major breakthrough
towards understanding PDA patho-biology was made by deciphering the molecular events
responsible for the development of PDA [59, 60].
New chemo-therapeutic drugs are needed in PC. Targeting inflammatory pathways with anti-
inflammatory drugs may be of benefit for a combined, multi-target approach to PDA therapy.
Anti-inflammatory agents may potentiate the tumoural growth’s inhibitory effect of chemo‐
therapeutic agents, such as Gemcitabine.
6.1. Cyclooxygenase-2 (COX-2) inhibitors (specific and non-specific)
The selective inhibition of the Cox-2 gene expression and of its enzymatic activity may have
chemoprotective potential in high-risk patients for PC. Similar to familial adenomatous
polyposis (FAP) treated with sulindac, COX-2 inhibitor therapy may delay pancreatic cancer
precursor lesion progression and reduce the incidence of pancreatic cancers.
Experimental studies using a genetically modified mouse model of pancreatic cancer devel‐
opment (K-RasG12D; PDX-1-Cre mice, BOP treated hamster) and cell lines have shown efficacy
in reducing the development of high-grade pancreatic intraepithelial neoplasias (PanIN) and
ductal adenocarcinoma [61]. Cox-2 inhibitors such as etodolac, sulindac, celocoxib and
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nimesulide inhibited the proliferation of pancreatic cancer cells [62, 63]. The antitumoural
activity of aspirin, a nonsteroidal anti-inflammatory drug (NSAID), involves numerous
molecular targets, including Cox-2. Sclabas et al. showed that aspirin inhibits the activation of
the NF-kB pathway in cultured cells and decreased the expression of the COX-2 gene [42, 64].
Moreover, aspirin may activate adenosine monophosphate-activated protein kinase (AMPK),
and may affect Notch, Wnt/β-catenin, and other signalling pathways [65]. Nimesulide (4-
nitro-2 phenoxymethanesulfonanilide), another NSAID, significantly decreases PDA in mice
treated during the postinitiation phase of pancreatic carcinogenesis [66]. Moreover, the
progression of later stage PanIN was lowered by this drug [62]. While experimental data are
highly available, only a few clinical trials of pancreatic cancer using COX-2 inhibitors as
chemopreventive agents have shown a possible clinical benefit. A randomized phase II study
(Apricot-P) evaluated Apricoxib in combination with Gemcitabine and Erlotinib (Modiano M.
et al., personal communication). Similarly, celocoxib was also evaluated in combination with
Gemcitabine and Cisplatin in patients with metastatic PC or combined with Gemcitabin [67].
In both studies, the primary endpoint was a survival rate at six months, although no improve‐
ment in Gemcitabine activity has been observed.
6.2. TGF-β inhibitors
Traberdersen, a specific inhibitor of TGF-b2, was used as a 2nd line treatment in a phase I/II
study of 37 patients with PDA. The median survival was 13.4 months and one patient showed
a complete response [68]. Although the study is in an incipient phase, TGF-β shows to be a
promising clinical target.
6.3. Aspirin
In vitro findings suggest that aspirin might inhibit pancreatic carcinogenesis, but epidemio‐
logical data are inconsistent. There are studies indicating that nonsteroidal anti-inflammato‐
ry drugs (NSAIDs) reduce the risk of gastrointestinal (GI) cancers and pancreatic cancer,
but other results indicate that there is no significant association between aspirin use and
pancreatic  cancer  risk.  A  limited  number  of  populational-based  studies  are  available.
According  to  Streicher  SA  et  al.,  significant  relationships  between  aspirin  use  and  de‐
creased pancreas-cancer incidence and mortality have been shown in four out of 13 studies
[69].  In some studies the benefit  was positively correlated with the frequency of aspirin
intake [70].  In a systematic review and meta-analysis,  Cui X et  al.  analysed the associa‐
tion between aspirin intake and its  effect  for  the chemoprevention of  pancreatic  cancer.
They carried out  a  total  of  10  studies  (four case-control  studies,  five  prospective cohort
studies, and one randomized controlled trial) published between 2002 to 2011 with 7,252
cases of pancreatic cancer and more than 120,0000 healthy control subjects enrolled in the
studies. The conclusion of the study was that high-dose, rather than low-dose, aspirin intake
was associated with an 0.88-fold decreased risk for pancreatic cancer compared with non-
use [71]. Table 1 overviews the information from studies that analysed the association of
the aspirin or NSAID intake with pancreatic cancer.
Chronic Pancreatitis as an Inductor of Pancreatic Cancer — Correlations With Inflammatory Pathways
http://dx.doi.org/10.5772/59714
215
Study design No of patients Period Drug type Dose and
duration of
NSAID use
Conclusions
Prospective
cohort study
[72]
28,283 postmenopausal
women- 80 incident cases of
pancreatic cancer
1992 to
1999
Aspirin and other
NSAIDs
Not collected Aspirin might be
chemopreventive for
pancreatic cancer
Case-control
Surveillance
Study [73]
149 patients with pancreatic
cancer (n = 504), stomach (n =
254), oesophagus (n = 215),
gallbladder (n = 125), or liver
(n = 51) and Controls were
5,952 ( non tumoral diseases)
1977 to
1998
Salicylates (e.g.,
aspirin), indoles
(e.g.,
indomethacin),
propionic acids
(e.g., ibuprofen),
fenamates (e.g.,
mefenamic acid),
and/or oxicams
(e.g., piroxicam).
At least four
days/week for at
least three
months, initiated
at least one year
before admission.
No effect of NSAID use
Case-control
study [74]
12,174 incident cancer cases
(396 pancreatic cancer) and
34,934 controls
1993 to
1995
13–36 months
before cancer
diagnosis
13-36 months
before cancer
diagnosis
The increased risks of
pancreatic cancer could
be due to chance or to
undetected biases
Clinic-based
case-control
study [75]
904 cases and 1,224 controls April 2004
to
September
2010
Aspirin, NSAID
and acetaminophen
Aspirin use ≥ 1
day/month
Aspirin use, but not non-
aspirin NSAID use, is
associated with a
lowered risk of
developing pancreatic
cancer
Hospital-based
case-control
study ( Roswell
Park Cancer
Institute) [76]
194 patients with pancreatic
cancer were compared to 582
age and sex-matched patients
with non-neoplastic condition
1982 to
1998
Aspirin At least one tablet
per week for at
least six months
was classified as
regular aspirin
use.
Regular aspirin use may
not be associated with a
lower risk of pancreatic
cancer
Multicentric
hospital-based
case-control
study in Italy
[77]
308 patients with incident
pancreatic cancer and
controls were 477 with acute
conditions
1991 and
2008
22 cases (7%) and
37 controls (8%) -
regular aspirin
Nonregular use No association between
regular aspirin use and
pancreatic cancer risk,
although our results
suggested a possible
protective effect for long-
term current users
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Study design No of patients Period Drug type Dose and
duration of
NSAID use
Conclusions
Prospective
cohort study
[78]
161 cases with pancreatic
cancer ( 88,378 women
without cancer at the
baseline)
1980 to
1998
Aspirin Two or more
standard tablets
per week
Extended periods of
regular aspirin use
appear to be associated
with a statistically
significantly increased
risk of pancreatic cancer
among women
Population-
based cohort
study [79]
11,683 patients with
rheumathoid arthritis, 840
patients with cancer, 32 with
pancreatic cancer
1965 to
1983
NSAID No information
regarding doses
Slightly reduced risk for
pancreatic cancer
Population-
based
Connecticut
study [69]
362 pancreas-cancer cases
frequency matched to 690
randomly sampled controls.
2005 to
2009
Aspirin ( low dose,
regular dose)
Daily Daily aspirin regimen
may reduce risk of
developing pancreatic
cancer
Prospective
cohort study
[80]
Cancer Prevention Study II
(CPS-II) cohort- 98,7590
4,577 deaths from pancreatic
cancer
1982 to
2000
Aspirin Frequent aspirin
use (> or =30
times per month)
Aspirin use was not
associated with
pancreatic cancer
mortality
7. The “therapeutic” role of surgical treatment in the progression of chronic
pancreatitis to PDA
Pancreas resection is indicated in CP patients who have small-duct disease or those in whom
endoscopic drainage fails.
There are experimental and clinical studies that take into consideration the fact that the surgical
treatment of chronic pancreatitis may reduce the risk of the development of PDA. Even though
the mechanism of the protective role of surgery remains unknown, possible explanations could
be linked to the fact that through the endoscopic drainage procedures or resection procedures
of the CP, pancreatic tissue and the inflamed tissue are removed or diminished. Ueda J et al.
have found that patients who underwent surgical treatment for chronic pancreatitis had a
significantly lower incidence of pancreatic cancer. According to this study, 5.1% of patients
who had not received surgical treatment for CP developed pancreatic cancer, whereas PDA
was observed in 0.7% of patients who had undergone surgery for chronic pancreatitis [81].
G.H. Sakorafas et al. reviewed the experience of 484 consecutive patients who underwent
surgery for chronic pancreatitis; pancreatic cancer was diagnosed after a mean of 3.4 years
after the initial operation for chronic pancreatitis in 2.9% of the 484 patients [82]. Even though
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the percentage of patients who underwent pancreatic resection for CP and subsequently
developed PDA is higher than in the study by Ueda J et al., it is smaller than in the studies that
analyse patients with CP without surgical treatment.
8. Conclusions
The  tumour  microenvironment  is  a  critical  determinant  of  PDA  progression  and  treat‐
ment outcome. From the above presented studies, it is clear that CP may be considered as
a  prerequisite  of  the  PDA condition.  The major  evidence supporting this  assumption is
based on  studies  revealing  that  the  tumour  microenvironment  of  the  ductal  epithelium
increases  the  risk  of  neoplastic  transformation.  In  the  onset  of  CP,  the  pathways  and
molecules  described  so  far  are  activated  and  promote  the  transformation  from  normal
epithelium to metaplasmic, early neoplasmic lesions (PanIN) and finally pancreatic cancer.
Despite the fact that many studies determined that inflammatory components and down‐
stream effectors are present in both CP and pancreatic cancers, there is not a clear common
pathway for pancreatic cancer development which includes chronic inflammatory process‐
es  and finally  stroma formation.  When revealed,  these  findings  may guide  us  to  novel
strategies for pancreatic cancer therapy.
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